Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313

• Date : 2022-09-14
• 21    
  1

Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD

• Date : 2022-09-14
• 16    
  0

Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study

• Date : 2022-09-14
• 15    
  0

Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study

• Date : 2022-09-14
• 9    
  0

Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801

• Date : 2022-09-14
• 8    
  0

Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study

• Date : 2022-09-14
• 8    
  0

Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study

• Date : 2022-09-14
• 6    
  0

Congrès ESMO 2026

• Date : 2026-10-23
• 50    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 2025-12-10
• 131    
  0

SABCS 2025 Symposium

• Date : 2025-12-09
• 5324    
  0

Congrès ESMO Asie 2025

• Date : 2025-12-05
• 302    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 2025-11-13
• 461    
  0